on January 8, 2004
Published online before print January 8, 2004, doi: 10.1161/01.ATV.0000116216.56511.39
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 5, 2003
Accepted on December 23, 2003
Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?
Steve E. Humphries ;
From Centre for Cardiovascular Genetics (S.E.H., P.J.T.), British Heart Foundation Laboratories, Rayne Building, Royal Free and University College London Medical School, London, UK; and The Centre for Cardiovascular Disease Prevention (P.M.R.), Divisions of Cardiovascular Diseases and Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
* To whom correspondence should be addressed. E-mail: p.talmud{at}ucl.ac.uk.
Abstract--Genetic susceptibility tests are already advertised on the Internet to identify individuals at above average risk for cardiovascular disease (CVD), such as deep vein thrombosis, hyperlipidemia, or atherosclerosis, whereas other tests claim to predict response to a particular drug treatment. Some kits are available to the public directly, bypassing a doctor. Their value, however, must be considered carefully, because although a genotype may be strongly and consistently associated with an intermediate trait, and because the intermediate trait is a strong predictor of CVD risk, there may be little or no association of genotype with risk over and above that of the measured trait. This is because multigenic effects and environmental modification (context dependency) of genotype effects determine CVD risk. An individual’s personal characteristics and plasma risk-trait levels (which reflect both genotype and exposure) at present are the best predictors of clinical outcome. Only when genetic tests surpass this, possibly by the inclusion of many functional common variants, in conjunction with their context-dependent effects on risk, might their usefulness in clinical management be realized. Here we review some of the particular issues and concerns raised by CVD-risk genetic testing, and suggest areas of further research to address these issues.
This article has been cited by other articles:
 |
|
 |
|
  P. J. Talmud, J. A. Cooper, J. Palmen, R. Lovering, F. Drenos, A. D. Hingorani, and S. E. Humphries Chromosome 9p21.3 Coronary Heart Disease Locus Genotype and Prospective Risk of CHD in Healthy Middle-Aged Men Clin. Chem., March 1, 2008; 54(3): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Humphries, J. A. Cooper, P. J. Talmud, and G. J. Miller Candidate Gene Genotypes, Along with Conventional Risk Factor Assessment, Improve Estimation of Coronary Heart Disease Risk in Healthy UK Men Clin. Chem., January 1, 2007; 53(1): 8 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Podgoreanu and D. A. Schwinn New Paradigms in Cardiovascular Medicine: Emerging Technologies and Practices: Perioperative Genomics J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1965 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Monraats, N. M.M. Pires, W. R.P. Agema, A. H. Zwinderman, A. Schepers, M. P.M. de Maat, P. A. Doevendans, R. J. de Winter, R. A. Tio, J. Waltenberger, et al. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions Circulation, October 18, 2005; 112(16): 2417 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Burke Contributions of Public Health to Genetics Education for Health Care Professionals Health Educ Behav, October 1, 2005; 32(5): 668 - 675. [Abstract] [PDF]
|
|
|
|
|
|
F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]
|
|